文献速递造血干细胞移植与细胞治疗淋巴瘤

靶向Sirt-1通过抑制T细胞同种反应并促进Treg稳定性控制小鼠GVHD

Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
PubMed 文献 · Blood · 2018-12-04

该研究利用Sirt-1条件性敲除小鼠及Sirt-1抑制剂Ex-527,在主要组织相容性复合体(MHC)错配与MHC匹配的小鼠骨髓移植模型中,发现Sirt-1缺失的T细胞通过增强p53乙酰化降低诱导急性GVHD的能力,并促进诱导性调节性T细胞(iTreg)分化、抑制干扰素-γ产生。Sirt-1抑制剂Ex-527显著改善受体生存与临床评分,且无肿瘤复发迹象;Sirt-1缺失T细胞也显著降低诱导慢性GVHD的能力。

要点

  • Sirt-1缺失T细胞通过增强p53乙酰化降低诱导急性GVHD的能力。
  • Sirt-1抑制剂Ex-527改善受体生存与临床评分,无肿瘤复发迹象。
  • Sirt-1缺失T细胞显著降低诱导慢性GVHD的能力。

核心结论

  • Sirt-1抑制可减轻GVHD同时保留移植物抗白血病效应。
  • Sirt-1是控制急性和慢性GVHD发病的有前景治疗靶点,具有较高临床应用潜力。

研究设计与样本

  • 研究采用Sirt-1条件性敲除小鼠及药理学Sirt-1抑制剂Ex-527,在主要组织相容性复合体(MHC)错配与MHC匹配的小鼠骨髓移植(BMT)模型中开展。

主要发现

  • Sirt-1-/- T细胞通过增强p53乙酰化降低诱导急性GVHD的能力。
  • Sirt-1缺失T细胞促进诱导性调节性T细胞(iTreg)分化并抑制同种BMT后干扰素-γ产生。
  • iTreg中Sirt-1缺失增加Foxp3稳定性并限制iTreg转化为致病性T细胞。
  • 给予Sirt-1抑制剂Ex-527显著改善受体生存与临床评分,且无肿瘤复发迹象。
  • Sirt-1缺失T细胞显著降低诱导慢性GVHD的能力,机制涉及增强脾脏B细胞重建、减少滤泡性辅助性T细胞发育、调节供体B细胞反应降低B细胞活化与浆细胞分化。

临床怎么用

  • 治疗性Sirt-1抑制既可预防慢性GVHD,也可减轻已建立的慢性GVHD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains one of the major complications after allogeneic bone marrow transplantation (allo-BMT). Sirtuin-1 (Sirt-1) plays a crucial role in various biological processes including cellular senescence, metabolism, and inflammatory responses. Sirt-1 deacetylation regulates different transcription factors that are important for modulating immune responses. In the current study, we addressed the role of Sirt-1 in GVHD induction by employing Sirt-1 conditional knockout mice as well as a pharmacological Sirt-1 inhibitor. Using major histocompatibility complex (MHC)-mismatched and MHC-matched murine BMT models, we found that Sirt-1-/- T cells had a reduced ability to induce acute GVHD (aGVHD) via enhanced p53 acetylation. Sirt-1-deficient T cells also promoted induced regulatory T cell (iTreg) differentiation and inhibited interferon-γ production after allo-BMT. Sirt-1 deletion in iTregs increased Foxp3 stability and restrained iTreg conversion into pathogenic T cells. Furthermore, we found that administration with a Sirt-1 inhibitor, Ex-527, significantly improved recipient survival and clinical scores, with no signs of tumor relapse. These results indicate that Sirt-1 inhibition can attenuate GVHD while preserving the graft-versus-leukemia effect. Consistently, Sirt-1-deficient T cells also displayed a remarkably reduced ability to induce chronic GVHD (cGVHD). Mechanistic studies revealed that Sirt-1 deficiency in T cells enhanced splenic B-cell reconstitution and reduced follicular T helper cell development. Sirt-1 deficiency in T cells modulated donor B-cell responses reducing both B-cell activation and plasma cell differentiation. In addition, therapeutic Sirt-1 inhibition could both prevent cGVHD and reduce established cGVHD. In conclusion, Sirt-1 is a promising therapeutic target for the control of aGVHD and cGVHD pathogenesis and possesses high potential for clinical application.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Daenthanasanmak A, Iamsawat S, Chakraborty P, et al. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice. Blood. 2018. PMID: 30514750. doi:10.1182/blood-2018-07-863233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。